Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01, Zacks reports. The business had revenue of $1.11 million for the quarter, compared to the consensus estimate of $3.62 million. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. During the same quarter in the prior year, the business posted ($0.38) EPS.
Taysha Gene Therapies Stock Performance
TSHA stock traded up $0.24 during trading on Tuesday, reaching $2.28. The stock had a trading volume of 1,762,191 shares, compared to its average volume of 2,522,804. The stock’s 50 day moving average is $2.62 and its two-hundred day moving average is $2.55. The firm has a market cap of $426.41 million, a PE ratio of -4.65 and a beta of 0.41. Taysha Gene Therapies has a 52 week low of $1.27 and a 52 week high of $4.32. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75.
Insider Activity
In related news, major shareholder Paul B. Manning purchased 1,333,333 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was acquired at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the completion of the acquisition, the insider now owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.70% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on Taysha Gene Therapies
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Further Reading
- Five stocks we like better than Taysha Gene Therapies
- With Risk Tolerance, One Size Does Not Fit All
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- What is a Bond Market Holiday? How to Invest and Trade
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Utilities Stocks Explained – How and Why to Invest in Utilities
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.